{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:29:22Z","timestamp":1787318962923,"version":"build-2736575974"},"reference-count":183,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Govan Mbeki Research and Development Council, University of Fort Hare, Medical Research Council, and National Research Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Colorectal cancer is a common cancer in both men and women. Numerous studies on the therapeutic effectiveness of nanoparticles against colorectal cancer have been reported. Platinum treatments as well as other medications comprising of nanoparticles have been utilized. Drug resistance restricts the use of platinum medicines, despite their considerable efficacy against a variety of cancers. This review reports clinically licensed platinum medicines (cisplatin, carboplatin, and oxaliplatin) combined with various nanoparticles that have been evaluated for their therapeutic efficacy in the treatment of colorectal cancer, including their mechanism of action, resistance, and limitations.<\/jats:p>","DOI":"10.3390\/ijms231911261","type":"journal-article","created":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T23:13:27Z","timestamp":1664147607000},"page":"11261","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy"],"prefix":"10.3390","volume":"23","author":[{"given":"Buhle","family":"Buyana","sequence":"first","affiliation":[{"name":"Department of Chemistry, University of Fort Hare, Alice 5700, Eastern Cape Province, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobeka","family":"Naki","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Fort Hare, Alice 5700, Eastern Cape Province, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7100-4007","authenticated-orcid":false,"given":"Sibusiso","family":"Alven","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Fort Hare, Alice 5700, Eastern Cape Province, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessing Atim","family":"Aderibigbe","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Fort Hare, Alice 5700, Eastern Cape Province, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccell.2018.03.010","article-title":"Comparative molecular analysis of gastrointestinal adenocarcinomas","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Marmol, M.J.R., Sanchez-De-Diego, C., Dieste, A.P., Cerrada, E., and Rodriguez Yoldi, M.J. (2017). Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010197"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/djz093","article-title":"Immunotherapy for colorectal cancer: A review of current and novel therapeutic approaches","volume":"111","author":"Franke","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","first-page":"67","article-title":"Modifiable and non-modifiable risk factors of colorectal cancer","volume":"Volume 7","author":"Duncan","year":"2018","journal-title":"Advances in Health and Disease"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/j.clcc.2018.05.008","article-title":"Stage-based Variation in the E ect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival","volume":"17","author":"Lee","year":"2018","journal-title":"Clin. Color. Cancer."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcancer.2019.06.017","article-title":"Engineered nanoparticles for imaging and drug delivery in colorectal cancer","volume":"69","author":"Pavitra","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2010.05.003","article-title":"Site-specific drug delivery systems within the gastro-intestinal tract: From the mouth to the colon","volume":"395","author":"Pinto","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10611860701603281","article-title":"Colon-specific drug delivery for mebeverine hydrochloride","volume":"15","author":"Omar","year":"2007","journal-title":"J. Drug Target."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fphar.2019.00152","article-title":"Curcumin nanoformulations for colorectal cancer: A review","volume":"10","author":"Wong","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2217\/nnm-2016-0194","article-title":"Targeted nanoparticles for colorectal cancer","volume":"11","author":"Cisterna","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13238-015-0164-2","article-title":"Intranasal and oral vaccination with protein-based antigens: Advantages, challenges and formulation strategies","volume":"6","author":"Wang","year":"2015","journal-title":"Protein Cell."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.addr.2016.06.006","article-title":"Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs","volume":"106","author":"Griffin","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1080\/17425247.2016.1200554","article-title":"Advances in oral delivery of anti-cancer prodrugs","volume":"13","author":"Jain","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_18","first-page":"20","article-title":"Oral and intra-nasal administration of nanoparticles in the cerebral ischemia treatment in animal experiments: Considering its advantages and disadvantages","volume":"15","author":"Alavian","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: Strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.48.080907.180426","article-title":"The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy","volume":"48","author":"Hall","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/092986709787458452","article-title":"Metallothioneins and Platinum(II) Anti-Tumor Compounds","volume":"16","author":"Knipp","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: The role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1535-7163.MCT-07-0450","article-title":"Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds","volume":"7","author":"Benedetti","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fricker, S.P. (2007). Metal based drugs: From serendipity to design. Dalt. Trans., 4903\u20134910.","DOI":"10.1039\/b705551j"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/1061186X.2014.921924","article-title":"Research on application of computer database technology in information management","volume":"22","author":"Cai","year":"2014","journal-title":"Drug Target."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4103\/0973-1482.136621","article-title":"Concurrent chemo-irradiation with weekly cisplatin and paclitaxel in the treatment of locally advanced squamous cell carcinoma of cervix: A phase II study","volume":"10","author":"Varghese","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/cncr.28767","article-title":"A randomized phase 2 trial of gemcitabine\/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma","volume":"120","author":"Hussian","year":"2014","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10865","DOI":"10.1039\/C4NR03693J","article-title":"Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma","volume":"6","author":"Setua","year":"2014","journal-title":"Nanoscale"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1351\/pac200779122243","article-title":"Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology","volume":"79","author":"Hannon","year":"2007","journal-title":"Pure Appl. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"Wheate","year":"2010","journal-title":"Dalt. Trans."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/092986709788453087","article-title":"The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship","volume":"16","author":"Montana","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1535-7163.MCT-08-0659","article-title":"Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer","volume":"8","author":"Malumbres","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0006-2952(03)00260-0","article-title":"DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells","volume":"66","author":"Faivre","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2018.01.009","article-title":"The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions","volume":"360","author":"Bergamo","year":"2018","journal-title":"Coord. Chem. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/cmdc.201500478","article-title":"Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies","volume":"11","author":"Palermo","year":"2016","journal-title":"Chem. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10681","DOI":"10.1039\/b918871c","article-title":"The mechanism of action of platinum anticancer agents-what do we really know about it?","volume":"48","author":"Gibson","year":"2009","journal-title":"Dalt. Trans."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"111070","DOI":"10.1016\/j.jinorgbio.2020.111070","article-title":"Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action","volume":"207","author":"Khoury","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schoch, S., Gajewski, S., Rothfu\u00df, J., Hartwig, A., and K\u00f6berle, B. (2020). Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186928"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/JEP.S267383","article-title":"Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy","volume":"13","author":"Tchounwou","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1590\/S1984-82502014000400004","article-title":"Carboplatin: Molecular mechanisms of action associated with chemoresistance","volume":"50","author":"Wlodarczyk","year":"2014","journal-title":"Brazilian J. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: Comparative review of therapeutic management in solid malignancies","volume":"102","author":"Ho","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ica.2012.01.028","article-title":"Inorganica Chimica Acta Understanding how the platinum anticancer drug carboplatin works: From the bottle to the cell","volume":"389","author":"Pasqua","year":"2012","journal-title":"Inorganica Chim. Acta."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1040-8428(00)00070-6","article-title":"Oxaliplatin clinical activity  A review","volume":"35","author":"Misset","year":"2000","journal-title":"Crit. Rev. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3816\/CLC.2010.n.003","article-title":"Review Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer","volume":"11","author":"Raez","year":"2010","journal-title":"Clin. Lung Cancer."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ctrv.2007.01.009","article-title":"Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review","volume":"33","author":"Stordal","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","article-title":"Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma","volume":"104","author":"Yamasaki","year":"2011","journal-title":"Br. J. Cancer."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalt. Trans."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"120788","DOI":"10.1016\/j.ijpharm.2021.120788","article-title":"Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs","volume":"605","author":"Boztepe","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1124\/mol.106.022624","article-title":"Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin","volume":"70","author":"Holzer","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1139\/cjpp-2015-0530","article-title":"Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein","volume":"94","author":"Yuan","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/cncr.28234","article-title":"Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","article-title":"Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients wit advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines","volume":"7","author":"Machover","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X","article-title":"A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumour effectiveness against metastatic colorectal cancer","volume":"69","author":"Misset","year":"1992","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil\u2013leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"Figer","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil\u2013leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil\u2013leucovorin: Interim results of a Phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_61","first-page":"473","article-title":"T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer","volume":"10","author":"Fu","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00258461","article-title":"Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma","volume":"23","author":"Petrelli","year":"1989","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00000421-198910000-00011","article-title":"A phase II study of carboplatin and CHIP in patients with metastatic colon carcinoma","volume":"12","author":"Asbury","year":"1989","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/0959-8049(93)90085-T","article-title":"Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines","volume":"29","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00000421-198812000-00012","article-title":"Phase II trial of iproplatin (CHIP) in previously untreated patients with colorectal cancer","volume":"11","author":"Blitzer","year":"1988","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00001813-199402000-00010","article-title":"Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in LoVo and LoVo\/PDD cells","volume":"5","author":"Han","year":"1994","journal-title":"Anti-Cancer Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/1078-0432.CCR-03-0315","article-title":"A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors","volume":"10","author":"Terret","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-05-2169","article-title":"Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system","volume":"12","author":"Rice","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bc0600517","article-title":"Synthesis and Characterization of AP5346, a Novel Polymer-Linked Diaminocyclohexyl Platinum Chemotherapeutic Agent","volume":"17","author":"Sood","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"ref_70","first-page":"255","article-title":"Preclinical development of AP5346: A dachplatinum polymer conjugate","volume":"91","author":"Stewart","year":"2003","journal-title":"J. Contol. Release."},{"key":"ref_71","first-page":"1515","article-title":"Poly(amidoamine) dendrimer-supported organoplatinum antitumour agents","volume":"466","author":"Howell","year":"2009","journal-title":"Proc. R. Soc. A Math. Phys. Eng. Sci."},{"key":"ref_72","first-page":"897","article-title":"Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer","volume":"31","author":"Yellepeddi","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/IJN.S8595","article-title":"Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines","volume":"5","author":"Haririan","year":"2010","journal-title":"Int. J. Nanomed."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1021\/bc900406m","article-title":"Platinum(II)\u2212Dendrimer Conjugates: Synthesis and Investigations on Cytotoxicity, Cellular Distribution, Platinum Release, DNA, and Protein Binding","volume":"21","author":"Kapp","year":"2010","journal-title":"Bioconj. Chem."},{"key":"ref_75","first-page":"3","article-title":"Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts","volume":"12","author":"Boulikas","year":"2004","journal-title":"Oncol. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.addr.2013.09.014","article-title":"Nanocarriers for delivery of platinum anticancer drugs","volume":"65","author":"Oberoi","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mabi.201100320","article-title":"Influence of corn straw Fibers and polymer latexes on vibration damping property of cement-based materials","volume":"12","author":"Xiao","year":"2012","journal-title":"Macromol. Biosci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1016\/j.biomaterials.2011.06.072","article-title":"Biodegradable polymer -cisplatin(IV) conjugate as a pro-drug of cisplatin(II)","volume":"32","author":"Xiao","year":"2011","journal-title":"Biomaterials"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2013.10.020","article-title":"Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo","volume":"173","author":"Xiao","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1016\/j.biomaterials.2012.08.015","article-title":"The use of polymeric platinum (IV) prodrugs to deliver multinuclear platinum (II) drugs with reduced systemic toxicity and enhanced antitumor efficacy","volume":"33","author":"Xiao","year":"2012","journal-title":"Biomaterials"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ica.2012.05.012","article-title":"Chrzanowski, Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic field","volume":"393","author":"Wheate","year":"2012","journal-title":"Inorg. Chim. Acta."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1021\/ic202197g","article-title":"Cisplatin-Tethered Gold Nanoparticles That Exhibit Enhanced Reproducibility, Drug Loading, and Stability: A Step Closer to Pharmaceutical Approval?","volume":"51","author":"Craig","year":"2012","journal-title":"Inorg. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11142","DOI":"10.1039\/c1jm11369k","article-title":"Superparamagnetic magnetite nanocrystal clusters as potential magnetic carriers for the delivery of platinum anticancer drugs","volume":"21","author":"Xing","year":"2011","journal-title":"J. Mater. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8914","DOI":"10.1021\/la904695a","article-title":"Isomer-Dependent Adsorption and Release of Cis- and Trans-platin Anticancer Drugs by Mesoporous Silica Nanoparticles","volume":"26","author":"Tao","year":"2010","journal-title":"Langmuir"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1021\/nn9015345","article-title":"Mesoporous Silica Microparticles Enhance the Cytotoxicity of Anticancer Platinum Drugs","volume":"4","author":"Tao","year":"2010","journal-title":"ACS Nano"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11584","DOI":"10.1021\/ja803383k","article-title":"Nanoscale Coordination Polymers for Platinum-Based Anticancer Drug Delivery","volume":"130","author":"Rieter","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_87","first-page":"14261","article-title":"Postsynthetic Modifications of Iron-Carboxylate Nanoscale Metal\u2212Organic Frameworks for Imaging and Drug Delivery","volume":"131","author":"Lin","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1038\/ncomms5182","article-title":"Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.colsurfb.2017.05.041","article-title":"Amino-functionalized nano-vesicles for enhanced anticancer efficacy and reduced myelotoxicity of carboplatin","volume":"157","author":"Zhu","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eurpolymj.2018.09.011","article-title":"Formulation of functionalized PLGA nanoparticles with folic acid- conjugated chitosan for carboplatin encapsulation","volume":"108","author":"Profirio","year":"2018","journal-title":"Eur. Polym. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fbioe.2019.00238","article-title":"Characterization of an Amphiphilic Phosphonated Calixarene Carrier Loaded With Carboplatin and Paclitaxel: A Preliminary Study to Treat Colon Cancer in vitro and in vivo","volume":"7","author":"Li","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_92","first-page":"109","article-title":"Cytotoxic evaluation of anticancer folate decorated carboplatin loaded albumin nanoparticles using folate receptor","volume":"64","author":"Abdelwahab","year":"2021","journal-title":"Az. J. Pharm Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/21691401.2021.1876718","article-title":"Antitumor activities of carboplatin\u2013doxorubicin\u2013ZnO complexes in different human cancer cell lines (breast, cervix uteri, colon, liver and oral ) under UV exposition","volume":"49","author":"Pairoj","year":"2021","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.arabjc.2017.05.011","article-title":"Nanoparticles: Properties, applications and toxicities","volume":"12","author":"Khan","year":"2019","journal-title":"Arab. J. Chem."},{"key":"ref_95","unstructured":"Ray, U. (2021, September 20). What Are the Different Types of Nanoparticles?. Azonano, Available online: www.azonano.com\/article.aspx?ArticleID=4938."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: Non viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Haider, M., Abdin, S.M., Kamal, L., and Orive, G. (2020). Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030288"},{"key":"ref_99","first-page":"578","article-title":"Lipid-based nanoparticles in the treatment of erectile dysfunction","volume":"32","author":"Guven","year":"2020","journal-title":"IJIR"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., and Shen, J. (2021). Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040520"},{"key":"ref_101","unstructured":"Xiaowei, D. (2009). Lipid-Based Paclitaxel and Doxorubicin Nanoparticles to Overcome P-Gpmediated Drug Resistance in Solid Tumors. [Ph.D. Thesis, University of Kentucky]. Available online: https:\/\/uknowledge.uky.edu\/gradschool_diss\/724."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2008.10.002","article-title":"Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles","volume":"133","author":"Zhao","year":"2009","journal-title":"J. Control. Release"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1080\/21691401.2017.1366338","article-title":"Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: Preparation, optimization, and in vitro evaluation","volume":"46","author":"Rajpoot","year":"2018","journal-title":"Artif. Cells Nanomed. Biotec."},{"key":"ref_105","first-page":"1152","article-title":"Solid Lipid Nanoparticles Delivery Systems for Colon Cancer Chemotherapy: A Critical Review","volume":"11","author":"Hussain","year":"2020","journal-title":"Sys. Rev. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"41090","DOI":"10.1038\/srep41090","article-title":"Synergistically enhanced selective intracellular uptake of anticancer drug carrier comprising folic acid conjugated hydrogels containing magnetite nanoparticles","volume":"7","author":"Kim","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_107","first-page":"2231","article-title":"Preparation, physicochemical characterization and in vitro evaluation of oxaliplatin solid lipid nanoparticles for the treatment of colorectal cancer","volume":"4","author":"Tummala","year":"2014","journal-title":"Indo Am. J. Pharm. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1179\/joc.2008.20.5.622","article-title":"Mini E: Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil\/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan-or oxaliplatin-based chemotherapy","volume":"20","author":"Nobili","year":"2008","journal-title":"J Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-006-0235-4","article-title":"Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer","volume":"58","author":"Dragovich","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"670124","DOI":"10.3389\/fbioe.2021.670124","article-title":"Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer","volume":"9","author":"Ying","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_111","first-page":"9","article-title":"Recent advances in nanocarrier based therapeutic and diagnostic tools for colorectal cancer","volume":"7","author":"Shaji","year":"2015","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2015.05.271","article-title":"Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer","volume":"210","author":"Garrido","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1039\/C6TB01925K","article-title":"Polymeric nanoparticles for colon cancer therapy: Overview and perspectives","volume":"4","author":"You","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3109\/10717544.2015.1084400","article-title":"Oxaliplatin immuno hybrid nanoparticles for active targeting: An approach for enhanced apoptotic activity and drug delivery to colorectal tumors","volume":"23","author":"Tummala","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-019-0981-7","article-title":"Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6750-11-21","article-title":"Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma","volume":"11","author":"Yang","year":"2011","journal-title":"BMC Biotechnol."},{"key":"ref_117","first-page":"3309","article-title":"Application of liposomal technologies for delivery of platinum analogs in oncology","volume":"8","author":"Liu","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_118","first-page":"1621","article-title":"PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma","volume":"25","author":"Yang","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zielinska, A., Carreir\u00f3, F., Oliveira, A.M., Neves, A., Pires, B., Venkatesh, N., Durazzo, A., Lucarini, M., Eder, P., and Silva, A.M. (2020). Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules, 25.","DOI":"10.3390\/molecules25163731"},{"key":"ref_120","first-page":"1","article-title":"Polymer nanoparticles-preparations, applications and future insights: A concise review","volume":"60","author":"Adhikari","year":"2021","journal-title":"Polym. Plast. Technol. Mater"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1021\/acsnano.0c01676","article-title":"Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis","volume":"14","author":"Guo","year":"2020","journal-title":"ACS Nano"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-017-2297-x","article-title":"Combination of Oxaliplatin and Vit.E-TPGS in Lipid Nanosystem For Enhanced Therapeutic Efficacy in Colon Cancers","volume":"35","author":"Wang","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/pharmaceutics12020193","article-title":"Effect of Oxaliplatin-Loaded Poly(d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer","volume":"12","author":"Luiza","year":"2020","journal-title":"Pharmaceutics"},{"key":"ref_124","first-page":"178","article-title":"Targeting delivery of oxaliplatin with smart PEG-modified PAMAM G4 to colorectal cell line: In vitro studies, Process","volume":"69","author":"Narmani","year":"2018","journal-title":"Biochem"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1039\/C9TB02289A","article-title":"Dendrimer nanoparticles for colorectal cancer applications","volume":"8","author":"Carvalho","year":"2020","journal-title":"J. Mater. Chem. B."},{"key":"ref_126","first-page":"118","article-title":"Development of pH-dependent chronomodulated delivery systems of 5-fluorouracil and oxaliplatin to treat colon cancer","volume":"12","author":"Gowda","year":"2020","journal-title":"Int. J. App. Pharm."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Maspes, A., Pizzetti, F., Rossetti, A., Makvandi, F., Sitia, G., and Rossi, F. (2021). Advances in Bio-Based Polymers for Colorectal Cancer Treatment: Hydrogels and Nanoplatforms. Ges, 7.","DOI":"10.3390\/gels7010006"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41467-019-09221-x","article-title":"Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors","volume":"10","author":"Duan","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"12499","DOI":"10.1038\/ncomms12499","article-title":"Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"7","author":"He","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nano.2009.03.002","article-title":"Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer","volume":"6","author":"Jain","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1248\/bpb.b13-00540","article-title":"Selective Delivery of Oxaliplatin to Tumor Tissue by Nanocarrier System Enhances Overall Therapeutic Efficacy of the Encapsulated Oxaliplatin","volume":"37","author":"Selim","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"ref_132","first-page":"41","article-title":"Development and characterization of targeted nanoparticles loaded with Oxaliplatin for colorectal cancer treatment","volume":"9","author":"Hassanzadeganroudsari","year":"2018","journal-title":"J. Nanomed. Nanotechnol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1016\/j.biomaterials.2012.03.023","article-title":"Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer","volume":"33","author":"Urbanska","year":"2012","journal-title":"Biomaterials"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Yang, C., and Merlin, D. (2020). Lipid-Based Drug Delivery Nanoplatforms for Colorectal Cancer Therapy. Nanomaterials, 10.","DOI":"10.3390\/nano10071424"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"676815","DOI":"10.1155\/2013\/676815","article-title":"Carbon Nanotubes: A Review on Structure and Their Interaction with Proteins","volume":"2013","author":"Saifuddin","year":"2013","journal-title":"J. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/3-540-39947-X_1","article-title":"Introduction to Carbon Materials Research","volume":"80","author":"Dresselhaus","year":"2001","journal-title":"Topics Appl. Phys."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Debnath, K.S., and Srivastava, R. (2021). Drug Delivery With Carbon-Based Nanomaterials as Versatile Nanocarriers: Progress and Prospects. Front. Nanotechnol., 644564.","DOI":"10.3389\/fnano.2021.644564"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Sundaram, P., and Abrahamse, H. (2020). Effective Photodynamic Therapy for Colon Cancer Cells Using Chlorin e6 Coated Hyaluronic Acid-Based Carbon Nanotubes. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134745"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Kukovecz, A., Kozma, G., and Konya, Z. (2013). Multi-Walled Carbon Nanotubes. Springer Handbook of Nanomaterials, Springer.","DOI":"10.1007\/978-3-642-20595-8_5"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1039\/C6BM00444J","article-title":"Development of a controlled-release drug delivery system by encapsulating oxaliplatin into SPIO\/MWNT nanoparticles for effective colon cancer therapy and magnetic resonance imaging","volume":"4","author":"Lee","year":"2016","journal-title":"Biomater. Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11095-012-0883-5","article-title":"PEGylated multi-walled carbon nanotubes for encapsulation and sustained release of oxaliplatin","volume":"30","author":"Wu","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Mordorski, B., and Friedman, A. (2017). Chapter 4\u2014Metal Nanoparticles for Microbial Infection. A Strategy to Address Microbial Drug Resistance Micro and Nano Technologies, Elsevier.","DOI":"10.1016\/B978-0-323-41625-2.00004-1"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/0975-7406.72127","article-title":"Introduction to metallic nanoparticles","volume":"2","author":"Mody","year":"2010","journal-title":"J. Pharm. Bioallied. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568011053765994","article-title":"Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy","volume":"5","author":"Wheate","year":"2005","journal-title":"Curr. Med. Chem Anti-Cancer Agents"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1021\/ja908117a","article-title":"Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin","volume":"132","author":"Brown","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_146","first-page":"26","article-title":"OXA-CuS@ UiO-66-NH2 as a drug delivery system for Oxaliplatin to colorectal cancer cells","volume":"33","author":"Gholami","year":"2022","journal-title":"J. Mater. Sci.: Mater. Med."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Jabalera, Y., Garcia-Pinel, B., Ortiz, R., Iglesias, G., Cabeza, L., Prados, J., Jimenez-Lopez, C., and Melguizo, C. (2019). Oxaliplatin\u2013Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11080395"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2174\/18715206113139990325","article-title":"Colon cancer therapy: Recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs","volume":"13","author":"Prados","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4155\/tde.10.13","article-title":"Nanoparticle-assisted combination therapies for effective cancer treatment","volume":"1","author":"Hu","year":"2010","journal-title":"Ther. Deliv."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","article-title":"Nanoparticle delivery of cancer drugs","volume":"63","author":"Wang","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/0929867322666151006094559","article-title":"Engineering nanomedicines to overcome multidrug resistance in cancer therapy","volume":"23","author":"Beretta","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.molmed.2019.08.012","article-title":"Applications of spherical nucleic acid nanoparticles as delivery systems","volume":"25","author":"Mokhtarzadeh","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1349-7006.2011.01941.x","article-title":"Nanomedicine in cancer therapy: Innovative trends and prospects","volume":"102","author":"Blanco","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/B978-0-12-416020-0.00012-7","article-title":"Nanoparticles in cancer chemotherapy","volume":"104","author":"Banerjee","year":"2011","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Li, S., Wang, A., Jiang, W., and Guan, Z. (2008). Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer., 8.","DOI":"10.1186\/1471-2407-8-103"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ejps.2008.08.008","article-title":"In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors","volume":"35","author":"Jain","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijbiomac.2019.01.101","article-title":"Lipophilic 5-fluorouracil prodrug encapsulated xylan-stearic acid conjugates nanoparticles for colon cancer therapy","volume":"128","author":"Kumar","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1078-0432.CCR-08-0515","article-title":"Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors","volume":"15","author":"Batist","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"7966","DOI":"10.1021\/acs.jafc.7b03093","article-title":"Chitosan-coated cinnamon\/oregano-loaded solid lipid nanoparticles to augment 5-fluorouracil cytotoxicity for colorectal cancer: Extract standardization, nanoparticle optimization, and cytotoxicity evaluation","volume":"65","author":"Kamel","year":"2017","journal-title":"J. Agric. Food Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.2147\/IJN.S257700","article-title":"Recent advances in designing 5-fluorouracil delivery systems: A stepping stone in the safe treatment of colorectal cancer","volume":"15","author":"Tayebi","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijpharm.2016.09.076","article-title":"Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells","volume":"513","author":"Safwat","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Cevenini, A., Celia, C., Orr\u00f9, S., Sarnataro, D., Raia, M., Mollo, V., Locatelli, M., Imperlini, E., Peluso, N., and Peltrini, R. (2020). Liposome-embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060559"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e1903296","DOI":"10.1002\/smll.201903296","article-title":"Ph Responsive PEG-shedding and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to enhance tumor-specific therapy","volume":"15","author":"Juang","year":"2019","journal-title":"Small"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/acsnano.8b06164","article-title":"Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer","volume":"13","author":"Liu","year":"2019","journal-title":"ACS Nano"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Huang, J.R., Lee, M.H., Li, W.S., and Wu, H.C. (2019). Liposomal irinotecan for treatment of colorectal cancer in a preclinical model. Cancers, 11.","DOI":"10.3390\/cancers11030281"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.colsurfb.2019.06.020","article-title":"Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer","volume":"181","author":"Cheng","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"17793","DOI":"10.1021\/acsami.6b04403","article-title":"Targeting Colorectal cancer stem-like cells with Anti-CD133 antibody conjugated SN-38 nanoparticles","volume":"8","author":"Ning","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.7150\/thno.38081","article-title":"Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer","volume":"9","author":"Han","year":"2019","journal-title":"Theranostics"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.2147\/IJN.S219820","article-title":"Co-Administration Of iRGD enhances tumor-targeted delivery and antitumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment","volume":"14","author":"Zhong","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1166\/jbn.2016.2283","article-title":"Superparamagnetic iron oxide nanorod carriers for paclitaxel delivery in the treatment and imaging of colon cancer in mice","volume":"12","author":"Dehvari","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.biomaterials.2011.01.027","article-title":"The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer","volume":"32","author":"Venkatesan","year":"2011","journal-title":"Biomaterials"},{"key":"ref_172","first-page":"1851","article-title":"Chitosan- Pluronic nanoparticles as oral delivery of anticancer gemcitabine: Preparation and in vitro study","volume":"7","author":"Hosseinzadeh","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/10837450.2011.640688","article-title":"Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon","volume":"18","author":"Chuah","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2010.08.023","article-title":"Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells","volume":"400","author":"Wang","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"118786","DOI":"10.1016\/j.ijpharm.2019.118786","article-title":"Aspirin-loaded nanoexosomes as cancer therapeutics","volume":"572","author":"Tran","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.nano.2018.05.020","article-title":"A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer","volume":"14","author":"Li","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1039\/C9BM00613C","article-title":"Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer","volume":"7","author":"Li","year":"2019","journal-title":"Biomater. Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1021\/acs.molpharmaceut.9b00867","article-title":"EpCAM Aptamer functionalized cationic liposome-based nanoparticles loaded with miR-139-5p for targeted therapy in colorectal cancer","volume":"16","author":"Zhao","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1476-5381.2011.01768.x","article-title":"Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells","volume":"166","author":"Minelli","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_180","first-page":"1535","article-title":"Suitable carriers for encapsulation and distribution of endostar: Comparison of endostar-loaded particulate carriers","volume":"6","author":"Chen","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.radonc.2019.07.029","article-title":"DNA damage enhancement by radiotherapy-activated hafnium oxide nanoparticles improves cGAS-STING pathway activation in human colorectal cancer cells","volume":"141","author":"Marill","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Gurunathan, S., Qasim, M., Park, C., Koo, H., Kim, J.H., and Hong, K. (2018). Cytotoxic potential and molecular pathway analysis of silver nanoparticles in human colon cancer cells HCT116. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082269"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/marc.201000341","article-title":"Enhanced in vivo magnetic resonance imaging of tumors by PEGylated iron-oxide-gold core-shell nanoparticles with prolonged blood circulation properties","volume":"31","author":"Kumagai","year":"2010","journal-title":"Macromol. Rapid Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11261\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:38:46Z","timestamp":1760143126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":183,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911261"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911261","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]}}}